Halozyme TherapeuticsHALO.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 16, 2026, Halozyme Therapeutics (HALO.O) trades at a P/E of 33.40x, P/B of 96.30x, P/S of 8.31x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 74th percentile over the trailing 10Y window (vs. 100th percentile over 3Y); P/B sits at the 97th percentile over the trailing 10Y window (vs. 92nd percentile over 3Y); P/S sits at the 41st percentile over the trailing 10Y window (vs. 96th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 66th percentile within its industry and the 74th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.48%, ranking at the 67th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 22.8 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Halozyme Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: HALO · HALO
Want the full picture on whether Halozyme Therapeutics (HALO.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 33.40 | ||||||
| P/B (MRQ) | 96.30 | ||||||
| P/S (TTM) | 8.31 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 2.48% |